Aripiprazole is the first antipsychotic to be introduced that has a mechanism of action that deviates from those of both conventional and atypical antipsychotics. It has a high affinity for the dopamine D₂ receptor (K_i=0.34 nmol), a level similar to that of haloperidol (K_i=0.7 nmol) but lower than that of other atypical antipsychotics (1). In vitro, aripiprazole acts as a partial agonist (1—4), a property that distinguishes it from the full-antagonist profile of all other conventional and atypical antipsychotic drugs (5). In a recent rodent study, the least effective dose to inhibit the conditioned avoidance response was associated with a striatal D₂ receptor occupancy exceeding 80%, in contrast to haloperidol and risperidone, which showed inhibition of the conditioned avoidance response at 60% occupancy (6). Furthermore, aripiprazole was not associated with any catalepsy, despite an occupancy exceeding 80% (6). Thus, in preclinical studies, aripiprazole has shown distinction from other antipsychotics at both the cellular and system levels.

In addition to its effects on D₂ receptors, aripiprazole also shows antagonism at 5-HT₂ receptors (K_i=8.7 nmol) (4) and partial agonism at 5-HT_1A receptors (K_i=1.65 nmol) (7). Aripiprazole differs from atypical antipsychotics (amisulpride excepted) in that it shows a lower in vitro affinity for 5-HT₂ receptors than for D₂ receptors (8). The 5-HT₂ occupancy of aripiprazole in human beings in vivo is unknown, although a recent preclinical study showed very low 5-HT₂ receptor occupancy in rats (median effective dose >30 mg/kg) (6). At 5-HT_1A receptors, aripiprazole shows levels of in vitro potency and intrinsic activity similar to those of ziprasidone (7), although little is known about the binding to 5-HT_1A receptors in human beings.

At clinically effective antipsychotic doses of 10—30 mg per day, aripiprazole carries a low risk of extrapyramidal side effects or elevation of prolactin levels (9). While preclinical studies have explored the contribution of aripiprazole’s pharmacological profile to its atypicality in terms of neurological side effects, no positron emission tomography (PET) studies have been conducted of this agent in patients with schizophrenia. In a previous PET study with healthy volunteers (10), subtherapeutic doses of aripiprazole (0.5 mg, 1 mg, and 2 mg per day) resulted in <80% striatal D₂ receptor occupancy at steady state, while therapeutic doses (10—30 mg per day) resulted in >80% striatal D₂ receptor occupancy without extrapyramidal side effects or prolactin elevation. These observations indicate a profile that contrasts with those of other antipsychotic drugs, which are associated with the emergence of extrapyramidal side effects and hyperprolactinemia at striatal D₂ occupancies >80%, and suggest that aripiprazole may show a higher D₂ occupancy threshold for both response and extrapyramidal side effects.

In light of aripiprazole’s unique in vitro profile, its partial agonist action at the D₂ receptors, claims about its pharmacological effects at 5-HT₂ and 5-HT_1A receptors, and its favorable clinical profile, we conducted a PET study to characterize its simultaneous effects at the D₂, 5-HT_1A, and 5-HT₂ receptors at therapeutic doses (10—30 mg/day) using three different radiotracers in patients with schizophrenia or schizoaffective disorder.

The study was approved by the Research Ethics Board of the Centre for Addictions and Mental Health, Toronto. After providing informed consent, all participants underwent a physical examination and a battery of laboratory assessments. We used a randomized block design, with three participants per dose level, in which patients with schizophrenia or schizoaffective disorder were assigned to receive 10 mg, 15 mg, 20 mg, or 30 mg of aripiprazole. Diagnoses were confirmed by use of the Mini-International Neuropsychiatric Interview (11). Previous antipsychotic medications other that olanzapine were discontinued and replaced by the assigned dose of aripiprazole, without taper or titration. Participants who were taking olanzapine were tapered from this drug over 7 days to minimize cholinergic withdrawal symptoms. No concomitant antipsychotic medications or change in other concomitant psychotropic medications were allowed during the study period. Patients with active substance abuse or a positive urine drug screen, as well as patients who had been treated with depot antipsychotic drugs within the previous 6 months, were excluded from the study. The following clinical assessments were conducted at baseline and then weekly thereafter: the Positive and Negative Syndrome Scale (PANSS) (12), the Clinical Global Impression scale (CGI) (13), the Global Assessment of Functioning Scale, the Simpson-Angus Rating Scale (14), the Barnes Rating Scale for Drug-Induced Akathisia (15), and the Abnormal Involuntary Movement Scale (16).

After at least 14 days of treatment with aripiprazole, participants underwent PET scanning using [¹¹C]raclopride, [¹⁸F]setoperone, and [¹¹C]WAY100635. Scanning was done 3—5 hours after administration of aripiprazole (peak plasma level=3—5 hours). The [¹¹C]raclopride and [¹¹C]WAY100635 scans, separated by an interval of at least 3 hours, were done on one day, and the [¹⁸F]setoperone scan on another. Venous blood was collected to assess plasma concentrations of drug and prolactin at the time of scanning. For plasma prolactin concentration, a chemiluminescent immunoassay with a sensitivity of 0.25 mg/liter (Access Immunoassay System, Prolactin 33530) was used. Plasma concentrations of aripiprazole and its principal metabolite, dehydroaripiprazole, were determined using a validated LC-API-MS/MS assay (Alta Analytical Laboratory, Inc., El Dorado Hills, Calif.).

PET scanning was done with a Siemens HRRT high-resolution neuro-PET camera system (Siemens Molecular Imaging, Knoxville, Tenn.) measuring radioactivity in 207 brain sections with a thickness of 1.2 mm each and an in-plane resolution of approximately 2.8 mm full width at half-maximum. Transmission scans were acquired immediately before emission scans using a single photon point source (¹³⁷Cs; T₅₀=30.2 years, Eg=662 keV); these were used to correct the emission scans for the attenuation of 511 keV photons through tissue and head support. A saline solution containing a mean of 9.8 mCi [¹¹C]raclopride (SD=0.7) with a specific activity (at time of injection) of 1,243 mCi/mmol (SD=294) was injected as a bolus into an intravenous line placed in an antecubital vein. Similar procedures were done for [¹¹C]WAY100635 scans (mean dose=9.2 mCi [SD=0.8], specific activity=1,633 mCi/mmol [SD=827]) and [¹⁸F]setoperone scans (mean dose=4.8 mCi/mmol [SD=0.2], specific activity=823 mCi/mmol [SD=619]). Emission data were acquired in list mode for the highest possible temporal resolution. Emission data were acquired over 60 minutes for the [¹¹C]raclopride scan and 90 minutes for the [¹¹C]WAY100635 and [¹⁸F]setoperone scans. Raw data were reconstructed by filtered-back projection to yield dynamic images. For the [¹¹C]raclopride PET images, data were analyzed in 28 frames (five 1-minute, twenty 2-minute, and three 5-minute frames); for the [¹¹C]WAY100635 images, in 18 frames (three 20-second, three 1-minute, three 2-minute, two 5-minute, and seven 10-minute frames); and for the [¹⁸F]setoperone images, in 22 frames (five 1-minute and seventeen 5-minute frames).

Participants underwent standard fast spin echo T1-weighted imaging (fast spoiled gradient echo, time to echo=5.3—15 msec, repetition time=8.9—12 msec, field of view=20 cm [three-dimensional], 256×256 voxel 1.5 isotropic, number of excitations=1) and a proton density image (time to echo=17, repetition time=6,000, field of view=22 cm [two-dimensional], 256×256, slice thickness=2 mm, number of excitations=2) acquired on a 1.5T Sigma-GE scanner. The T1 image was used for the analysis of the [¹¹C]WAY100635 and [₁₈F]setoperone scans, and the proton density image for the [¹¹C]raclopride scans.

The regions of interest were the caudate, putamen, and ventral striatum for the [¹¹C]raclopride scan and the frontal and temporal cortices for the [¹⁸F]setoperone and [¹¹C]WAY100635 scans, as these regions are rich in D₂, 5-HT_1A, and 5-HT₂ receptors, respectively. The cerebellar cortex, excluding the vermix, was used as the reference region for each of the three PET scans (17—19). Time activity curves were obtained from dynamic PET images in native space with reference to regions of interest generated with in-house software for semiautomated generation of regions of interest from the coregistered magnetic resonance images (20).

To calculate receptor occupancy, data were obtained from age- and sex-matched healthy subjects (N=23, N=13, and N=24, respectively, for the [¹¹C]raclopride, [¹¹C]WAY100635, and [¹⁸F]setoperone scans) using the same imaging protocols as described above and used to estimate the participants’ unmedicated binding potential. Previous studies have not shown a major effect of illness on [¹¹C]raclopride, [¹¹C]WAY100635, and [¹⁸F]setoperone binding potential (21—23). The outcome measure was the binding potential (BP), defined as the ratio of k3 to k4, where k3 and k4 are the rate constants of radioligand delivery and transfer out of the specifically bound compartment in a three-compartment model (24). Formally, BP=k3/k4=1/V2×B_max/K_d, where V2 is the volume of distribution of the radioligand in the nondisplaceable compartments (which is assumed to be constant between individuals), B_max is the receptor concentration, and K_d is the affinity (25). In this study, binding potential is taken as a measure of the available receptors in the region of interest. An estimate of the binding potential was obtained by use of the simplified reference tissue model (26, 27), using PMOD software, version 2.7 (PMOD Technologies, Ltd., Zurich, Switzerland).

Occupancy was calculated as the percentage reduction in binding potential obtained after treatment with aripiprazole when compared with age-matched healthy comparison subjects [(BP_healthy — BP_drug)/BP_healthy × 100]. In addition, for an alternative index of receptor occupancy as measured by [¹¹C]WAY100635, we measured the change in area under the curve for each region of interest as a function of treatment with aripiprazole (28).

Bivariate correlation analysis was used to examine the relationship between the primary variables of interest. Nonlinear regression analysis was used to evaluate the relationship between dose and D₂ receptor occupancy. Descriptive statistics were used to summarize clinical rating scale scores at baseline and 4 weeks, and within-group t tests were performed to test whether any of the changes were significantly different from zero.

Sixteen patients completed the informed consent procedure, and 12 patients completed the study imaging procedures. Two patients failed screening (one could not commit to the study schedule because of other commitments, and the other was no longer interested in participating). Two patients (both assigned to receive 30 mg aripiprazole) dropped out of the study (after 1 and 4 weeks, respectively) before completing the brain imaging procedures and were replaced. The reasons for study discontinuation were insomnia and seizure, respectively. The patient who suffered a seizure later acknowledged a lifelong history of seizures, and the one who complained of insomnia had been nonadherent with a previously prescribed valproic acid regimen during the study. Among the 12 patients who completed the imaging procedures, nine were male, and the mean age was 31 years (SD=7). Those who completed the study were diagnosed as having either schizophrenia (10 patients) or schizoaffective disorder (two patients); the self-reported mean age at first episode was 23 years (SD=4). At baseline, participants were either off antipsychotic medications (four patients) or taking risperidone (five patients; 2.5—6.0 mg/day), olanzapine (two patients; 10 mg/day and 30 mg/day), or clozapine (one patient, 100 mg/day).

Table 1 presents clinical rating scale scores at baseline and after 4 weeks of treatment with aripiprazole. Because the study was not designed to detect changes in clinical rating scales, these results are presented for descriptive purposes only. The following adverse events were reported during the study period: difficulty falling asleep or interrupted sleep (N=7), restlessness (N=5), dizziness (N=5), dystonia (N=1), nightmare (N=1), headache (N=1), nausea (N=1), decreased appetite (N=1), and seizure (N=1).

Mean plasma aripiprazole concentrations did not differ at the time of the three respective scans ([¹¹C]raclopride: 221 ng/ml [SD=179]; [¹¹C]WAY100635: 199 ng/ml [SD=173]; [¹⁸F]setoperone: 218 ng/ml [SD=176]). Mean plasma concentrations of dehydroaripiprazole were similar at the times of the three scans ([¹¹C]raclopride: 53 ng/ml [SD=26]; [¹¹C]WAY100635: 51 ng/ml [SD=26]; [¹⁸F]setoperone: 52 ng/ml [SD=27]). Mean plasma aripiprazole and dehydroaripiprazole levels for each dose group are listed in Table 2. A modest linear correlation was observed between dose and plasma levels of aripiprazole (r=0.67, p=0.02) and dehydroaripiprazole (r=0.63, p=0.03). Mean prolactin concentration decreased from 21 mg/liter (SD=16) at baseline to 9 mg/liter (SD=13) at the time of the [¹¹C]raclopride scan (mean change, 12 mg/liter [SD=21]). Only one participant, a female patient who had been off antipsychotic medication at the start of the study, showed an increase in prolactin concentration, from 6 mg/liter at baseline to 47 mg/liter at the time of the [¹¹C]raclopride scan (reference range=3—27 mg/liter).

We found high occupancy at striatal dopamine D₂ receptors (putamen, 86.6% [SD=3.7]; caudate, 92.9% [SD=5.7]; and ventral striatum, 91.0% [SD=4.0]). Even the lowest dose (10 mg) resulted in a mean occupancy of 85% (putamen range=81%—88%), and occupancy increased in a dose-related manner to a mean of 91% at the maximum dose of 30 mg (range=90%—94%). The D₂ occupancy in the putamen was lower than that in the caudate (p<0.001) and ventral striatum (p=0.01), while the latter two were not reliably distinguishable. As shown in Table 3, aripiprazole dose and plasma concentration showed a significant linear correlation with D₂ occupancy in all three regions of interest.

Drug occupancy was lower for 5-HT₂ receptors (temporal cortex: mean=54.0% [SD=15.3, range=30.9—79.2]; frontal cortex: 59.4% [SD=12.9, range=43.4—83.5]), and lowest for 5-HT_1A receptors (temporal cortex: mean=16.2% [SD=14.3, range=0—39]; frontal cortex: 16.5% [SD=13.8, range= —2.0 to 43.5]; F=323.63, df=2, 81, p<0.001 for pairwise comparisons in all cases) (Figure 1). There was no difference between frontal and temporal occupancy for 5-HT_1A receptors and 5-HT₂ receptors. 5-HT_1A and 5-HT₂ receptor occupancies exhibited no relationship with dose, plasma aripiprazole concentration, or plasma dehydroaripiprazole concentration (Table 3).

Extrapyramidal side effects occurred only in two of the four participants in whom D₂ occupancy exceeded 90%. One of them, in the 30 mg dose group, suffered dystonia and parkinsonism requiring treatment with benztropine; the other, in the 20 mg dose group, suffered increased tone in the upper extremities accompanied by an increase in plasma prolactin concentration. In both participants, the plasma aripiprazole concentration (442 ng/ml and 663 ng/ml, respectively) and dehydroaripiprazole concentration (78 ng/ml and 94 ng/ml, respectively) were substantially higher than the mean concentration within their respective dose group (see Table 2).

This is the first study to document the very high D₂ receptor occupancy in patients at clinically effective doses of aripiprazole. This finding is consistent with the observation of >80% striatal D₂ occupancy reported earlier in healthy subjects receiving 10 mg or 30 mg of aripiprazole (10). Plotting the dose-occupancy relationship using pooled data from the present study and the earlier study (subclinical dose-occupancy data from Yokoi et al. [10]) reveals the expected saturating hyperbolic relationship between dose and D₂ receptor occupancy. In contrast to all other conventional and atypical antipsychotics (with the exception of clozapine), for which the minimum therapeutic dose has been shown to correspond to an expected D₂ receptor occupancy around 60%—65%, the estimated aripiprazole dose associated with 60% D₂ receptor occupancy is closer to a subtherapeutic dose of 1 mg. The minimally effective dose of 10 mg is associated with occupancy closer to 85%, suggesting that the occupancy threshold for clinical response for aripiprazole is above 80%.

Only two participants suffered extrapyramidal side effects; both were among the four participants in whom D₂ occupancy exceeded 90%, which suggests the possibility that slow metabolizers or individuals who have higher drug concentrations for other reasons may be at higher risk of developing extrapyramidal side effects. The emergence of such symptoms only at D₂ occupancy exceeding 90% raises the possibility that the threshold for extrapyramidal side effects is closer to 90% for aripiprazole, compared with 80% for other antipsychotic drugs.

The observation of an occupancy threshold shift for clinical efficacy with aripiprazole compared with other classical dopamine D₂ antagonists is consistent with a recent preclinical study (6) showing dissociation between aripiprazole’s D₂ occupancy and its functional antagonism at D₂ receptors. Natesan et al. (6) showed that in contrast to the observed 60% receptor occupancy threshold for inhibition of the conditioned avoidance response (a preclinical predictor of antipsychotic efficacy) for haloperidol and risperidone, this threshold shifted to 86% for aripiprazole. This apparent shift in threshold for conditioned avoidance response inhibition in rodents and therapeutic response in human subjects is probably a function of the drug’s partial agonist profile at D₂ receptors.

This is also the first study to document aripiprazole’s occupancy of serotonin 5-HT₂ receptors, and our data confirm that aripiprazole binds to this receptor in human subjects in vivo. However, aripiprazole exhibits a higher occupancy at D₂ receptors (87% [SD=4%]) than at 5-HT₂ receptors (52% [SD=18]); in this regard, its profile is more similar to haloperidol’s than to those of atypical antipsychotics. This new finding is consistent with aripiprazole’s higher D₂ affinity in vitro as well as recent occupancy data from an in vivo rodent study (6), and it confirms that aripiprazole’s atypical profile in vivo is not related to a high 5-HT₂/D₂ binding profile.

Aripiprazole has been shown to bind with high affinity to recombinant human 5-HT_1A receptors (h5-HT_1A) (K_i=1.65 nmol) and to display a partial agonist pharmacological profile (E_max=68% of 5-HT) that is similar to ziprasidone in potency and intrinsic activity (E_max=79% of 5-HT) (7). This is important because partial agonism at the 5-HT_1A receptor has been postulated as a potential therapeutic mechanism in the alleviation of depression, anxiety, negative symptoms, and extrapyramidal side effects (29—31). In rodent studies, 5-HT_1A agonists have been found to diminish the propensity for catalepsy (29) and to attenuate prolactin elevation (32) induced by D₂ antagonists, which suggests a mechanistic role in the atypical profile of ziprasidone and aripiprazole. In this study, we found very low occupancy of aripiprazole at the 5-HT_1A receptor (mean=16%). However, it has been shown that when [¹¹C]WAY100635 is used, other partial agonists also show low occupancies in this range (22, 33). Whether the low occupancy we observed reflects the true state of affairs or is an underestimate resulting from the use of an antagonist radiotracer to measure agonist binding is not clear. Underestimation may arise from the fact that agonists bind predominantly to the high-affinity-state sites (G-protein coupled), while antagonists bind equally to both high- and low-affinity-state sites (G-protein uncoupled) (34, 35). Thus, even though an agonist may bind to a high proportion of the high-affinity-state sites, this may not necessarily be representative of the total receptor population. Nonetheless, a recent study (36) has questioned aripiprazole’s high efficacy at 5-HT_1A receptors and suggested that the experimental conditions used in previous research (7) may have amplified the detection of aripiprazole’s weak partial agonist activity and even attributed partial agonist activity to risperidone, which is virtually devoid of 5-HT_1A activity. This is consistent with results from recent rodent studies (37, 38) that failed to find a substantial role for aripiprazole’s 5-HT_1A partial agonism in the attenuation of catalepsy (37) or modulation of extracellular dopamine and serotonin in the prefrontal cortex and hippocampus, respectively (38), arguing against a major role for this receptor in aripiprazole’s atypical antipsychotic profile.

A number of limitations qualify our conclusions. First, the study was powered to provide reliable occupancy estimates and was not designed to detect major clinical changes. While the data do suggest that the relationship between occupancy and subjective wellness (which is generally negative for other antagonist antipsychotics) may be different for partial agonists, this finding awaits replication from larger clinical studies. Second, the total number of scans was limited by safety considerations and the study participants’ prior medication exposure. The absence of the participants’ own baseline data introduces some error in the estimated occupancy, although this would be expected to be small and would not detract from the conclusions drawn in this study. Third, most participants had been previously maintained on other antipsychotic drugs, although the design ensured that there would be at least a 2-week washout of previous medication, so the spillover effect of these medications would be expected to be negligible.

In summary, therapeutic doses of aripiprazole are associated with D₂ receptor occupancies of >80% in patients with schizophrenia and an increased risk of extrapyramidal side effects at >90% D₂ occupancy, particularly in susceptible individuals, which suggests a shift in occupancy threshold for both clinical effect and extrapyramidal side effects compared with other antipsychotic drugs. Aripiprazole’s high D₂/5-HT₂ binding profile in vivo contrasts with the profiles of other atypical antipsychotic drugs, which exhibit high 5-HT₂/D₂ binding, and is consistent with the drug’s in vitro affinity and ex vivo findings in rodents. Finally, we confirm binding at cortical 5-HT_1A receptors in vivo, although occupancy at this receptor is very low and its clinical significance unclear.